Lee Pharmaceuticals, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ronal Ford
- Full Time Employees
- 1
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 1434 Santa Anita Avenue South El Monte CA United States of America 91733
- IPO Date
- Apr 18, 1973
- CIK
- 0000058411
- Website
- leepharmaceuticals.com
- Similar Companies
- Business
- Lee Pharmaceuticals, Inc. Lee Pharmaceuticals, Inc. (LPHM), headquartered in Sheridan, Wyoming and founded in 2003, operates as a holding company primarily focused on the development, manufacturing, and marketing of pharmaceutical products through its subsidiaries, including facilities in Hyderabad, India. The company manufactures and exports a broad portfolio of active pharmaceutical ingredients (APIs) such as levocetirizine dihydrochloride, rosuvastatin calcium, montelukast sodium, lurasidone HCl, pantoprazole magnesium dihydrate, prasugrel HCl, rabeprazole sodium, dapoxetine HCl, saxagliptin HCl, and numerous others targeting therapeutic categories including anti-histamines, hyperlipidemics, anti-psychotics, anti-ulceratives, anti-platelets, anti-diabetics, and anti-coagulants; semi-finished dosage forms like sustained release, immediate release, and enteric coated/delayed release pellets (e.g., venlafaxine HCl pellets, fenofibrate pellets, clopidogrel pellets, omeprazole pellets, lansoprazole+domperidone pellets); intermediates and fine chemicals; and finished formulations such as tablets, MUPS, sachets, and granules. Its manufacturing facilities hold approvals from USFDA, EUGMP, and WHO GMP, enabling exports to over 30 countries across North America, Europe, Asia, Africa, South America, the Middle East, and Oceania, with a focus on generic APIs, innovative APIs, contract development and manufacturing services, and drug delivery systems for markets including anti-hypertensives, anti-ulceratives, and anti-diabetics. In recent developments, the company completed a reverse triangular merger with RONN Motor Group in February 2023 to shift toward zero-emission hydrogen-electric vehicle design, development, manufacturing, and marketing through its subsidiary RONN Motor Group, Inc., alongside a January 2022 change of control to Accelerate Global Market Solutions, Corp., marking a strategic pivot from traditional consumer health products like lip balms and antacids to advanced pharmaceuticals and clean energy technologies.
Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide
Gan & Lee Pharmaceuticals' Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: SUPER-1 and SUPER-2
Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management
Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions
Gan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Injection for Overweight or Obesity
Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks
ObesityWeek®️ 2024 | Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese Adults
Gan & Lee Pharmaceuticals' Three Innovative Drugs: GZR18 Injection, GZR4 Injection, and GZR101 Injection Achieve Primary Endpoints in Phase 2 Clinical Studies
Gan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)
Gan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial
Gan & Lee Pharmaceuticals Announces Significant Progress on New Diabetes and Obesity Treatments at the American Diabetes Association's 84th Scientific Sessions
Gan & Lee Pharmaceuticals to Present Groundbreaking Data on Three Innovative Products at the American Diabetes Association's 84th Scientific Sessions